Exact Sciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

exactsciences.com

Founded Year

1995

Stage

IPO | IPO

Total Raised

$47.51M

Date of IPO

1/31/2001

Market Cap

8.49B

Stock Price

52.79

About Exact Sciences

Exact Sciences (NASDAQ: EXAS) is an applied genomics company with a mission to contribute to the eradication of common cancers by applying advances in the field of genomics to facilitate early detection of diseases.

Exact Sciences Headquarter Location

441 Charmany Drive

Madison, Wisconsin, 53719,

United States

844-870-8870

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Exact Sciences

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Exact Sciences in 1 CB Insights research brief, most recently on Jul 31, 2019.

Expert Collections containing Exact Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Exact Sciences is included in 4 Expert Collections, including Cancer.

C

Cancer

105 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

M

Medical Devices

773 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

H

Health Monitoring & Diagnostics

905 items

At-home IVD test developers, at-home sample collection device developers, at-home testing service providers, and all other companies playing in the at-home testing ecosystem. Companies tagged as #AtHomeTestingEcosystem

Exact Sciences Patents

Exact Sciences has filed 131 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Genetics
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/23/2018

4/19/2022

Transcription factors, Molecular biology, Prostate cancer, Autoimmune diseases, Genetics

Grant

Application Date

3/23/2018

Grant Date

4/19/2022

Title

Related Topics

Transcription factors, Molecular biology, Prostate cancer, Autoimmune diseases, Genetics

Status

Grant

Latest Exact Sciences News

Catalio Capital Management Raises $381 Million for Oversubscribed Third Life Sciences Fund

May 3, 2022

Catalio’s Flagship Strategy Will Continue to Identify and Invest in Breakthrough Biomedical Technology Companies Founded by Serial Scientist-Entrepreneurs May 03, 2022 08:30 AM Eastern Daylight Time NEW YORK--( BUSINESS WIRE )--Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm, today announced the successful close of its third venture fund, Catalio Nexus Fund III (“Fund III” or the “Fund”), with more than $381 million in total capital commitments, exceeding its original $300 million target. The Fund received significant backing from current Catalio investors and a number of new, global institutional investors, foundations and endowments. Launched in 2020 and led by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, Catalio manages more than $1 billion in assets across its private equity, private credit, and public equities strategies. Fund III is Catalio’s largest closed-end fund to date. Previously, Catalio raised $15 million for Nexus Fund I and $100 million for Nexus Fund II. Consistent with the successful approach of its predecessor vehicles, Fund III will invest in breakthrough biomedical technology companies at all stages of growth, from inception to IPO. Many of the companies in which the Fund invests are founded by Catalio Venture Partners, a group of 36 world-renowned serial scientist-entrepreneurs at top-tier academic institutions in the U.S. and Europe, each with a successful track record of starting up and spinning out businesses. The Fund’s investment strategy will leverage this unique venture partnership structure, which provides the firm with proprietary investment opportunities and deep technical insights on prospective investments. Catalio’s Head of Marketing, Brandon Matz, said: “Our disciplined, solutions-based investment approach has helped us build a highly differentiated portfolio of industry-leading companies led by the brightest minds in the life sciences space. The strong support we received for our third fund demonstrates the confidence our investors have in our strategy of partnering with the top scientists and entrepreneurs in the world to bring innovative, game-changing, and life-saving therapies to market.” Dr. Diamantis Xylas, Catalio’s Head of Research, added: ‘‘Our pipeline across the biotech and life sciences space is as robust as ever, and we look forward to continuing to back exceptional scientist-entrepreneurs and identify attractive investments that deliver treatment options to patients in need and drive returns for our investors.” Catalio has been highly active since its formation two years ago. In addition to its headquarters in New York’s Flatiron district, it opened two additional offices, in Baltimore near Johns Hopkins Medicine and on London’s Baker Street; added talent across all facets of the organization, which has grown to over 28 employees; and invested in 45 companies. Other notable recent highlights include: Catalio led Octant, Inc.’s $80 million Series B funding round to accelerate the advancement of precision medicines for complex diseases, and invested alongside Andreessen Horowitz Bio Fund and Bristol Myers Squibb in April 2022; Catalio seeded Pheast Therapeutics, founded by Stanford University’s Dr. Irv Weissman, and co-led its launch and $76 million Series A funding round to develop novel checkpoint therapies to fight cancer in April 2022 (Dr. Weissman is also the founder of Forty Seven, Inc., which was acquired by Gilead for $5 billion in 2020); Five Catalio portfolio companies went public over the last year, including Recursion Pharmaceuticals (NASDAQ: RXRX), Compass Pathways (NASDAQ: CMPS) and ATAI Life Sciences (NASDAQ: ATAI); Catalio portfolio company Thrive Earlier Detection, founded by Catalio Venture Partner Dr. Bert Vogelstein at Johns Hopkins, was acquired by EXACT Sciences (NASDAQ: EXAS) for $2.15 billion in January 2021; Catalio participated in Series A funding for Affini-T’s, a cell therapy company founded by Catalio Venture Partner Dr. Phil Greenberg at Fred Hutch in March 2022 (Dr. Greenberg was also the founder of Juno Therapeutics, acquired by Celgene for $9 billion in 2018); and Catalio portfolio company Personal Genome Diagnostics was acquired by LabCorp (NYSE: LH) for $500 million in February 2022. About Catalio Capital Management Catalio Capital Management, LP, is a multi-strategy life sciences investment firm that focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics and data-driven insights. Catalio's Partnership includes over 36 world-renowned scientists with extensive academic bona fides who have each started several successful companies based on their research. Catalio has offices in New York, Baltimore, and London. For more information, visit www.cataliocapital.com . Contacts

Exact Sciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Exact Sciences Rank

  • When was Exact Sciences founded?

    Exact Sciences was founded in 1995.

  • Where is Exact Sciences's headquarters?

    Exact Sciences's headquarters is located at 441 Charmany Drive, Madison.

  • What is Exact Sciences's latest funding round?

    Exact Sciences's latest funding round is IPO.

  • How much did Exact Sciences raise?

    Exact Sciences raised a total of $47.51M.

  • Who are the investors of Exact Sciences?

    Investors of Exact Sciences include Flagship Pioneering, HLM Venture Partners, Mayo Foundation For Medical Education And Research, RS Investments, Greylock Partners and 13 more.

  • Who are Exact Sciences's competitors?

    Competitors of Exact Sciences include SimBioSys, EDP Biotech, X-Zell, Auspex, Probiodrug and 16 more.

You May Also Like

I
Idiomics

Idiomics, LLC is a biotechnology company providing health providers, healthcare payors and pharmaceutical companies informatics and biotechnology tools and platforms to personalize medical care to the individual patient.

B
Bauer BioMedical

Bauer BioMedical, LLC is at the forefront of technological advances in the field of Genetic Translational Medicine. The company is in the process of finding applications for the company's Intellectual Property in the fields of Preemptive Medicine and Theranostics.

EGeen International Logo
EGeen International

EGeen International is a privately held emerging biotechnology company focused on drug and diagnostic target discovery, and personalized medicine applications. EGeen has exclusive commercial rights to the information from the Estonian Genome Project, a major national effort in Estonia with the objective of gathering medical information and blood samples from consented population. The Company will continue to establish biopharmaceutical and pharmacogenetic collaborations with partners seeking to validate drug target candidates and genetic drug profiles. More information about the Company can be found at http://www.egeeninc.com

M
MODA Technology Partners

MODA Technology Partners is a provider of informatics solutions for pharmaceutical and biotechnology quality manufacturing

G
Genaissance Pharmaceuticals

Personalized medicine through population genomics and informatics.

R
RevDia

RevDia is a provider of a therapeutic diagnostic testing platform. The company's diagnostic testing platform is designed to detect an active periodontal infection. Its technology is intended to measure elevated levels of slgA in saliva that is specific to Aa and Pg virulence proteins, an attribute displayed by bacteria when it becomes pathogenic during an active infection.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.